Navigation Links
Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
Date:10/25/2007

Primary Analysis of Pivotal Trial to Be Available No Later Than July 2008

SAN DIEGO, Oct. 25 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced that an independent Data Monitoring Board (DMB) was recently convened to assess time to tumor progression (TTP) for patients in the control group of the Company's pivotal Phase 3 clinical trial of FavId(R). The DMB assessment, which was conducted in accordance with the clinical protocol under Favrille's Special Protocol Assessment (SPA) with the Food & Drug Administration (FDA), indicated that the control group behavior is consistent with data reported in the published literature. Based in part on the guidance provided by the DMB, Favrille has determined April 2008 to be the appropriate time for data cutoff of the Phase 3 trial. The Company anticipates that the analysis of the data will be completed and made available no later than July 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)

The Phase 3 trial is a randomized, double-blind, placebo controlled trial of FavId following Rituxan(R) treatment in patients with follicular B-cell non-Hodgkin's lymphoma (NHL). A total of 349 patients were randomly assigned to receive either FavId plus Leukine(R) (sargramostim, GM-CSF) or placebo plus Leukine following a course of Rituxan treatment. The primary endpoint of this trial is TTP.

"As we previously communicated, the rate of progression in our pivotal Phase 3 trial has slowed during the past 12 months," said John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille. "We believe this is a positive development, and it has shifted our focus for data cutoff and analysis to trial follow-up time as allowed in the protocol rather than the number of patient progressi
'/>"/>

SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
5. XTL Provides Update on Phase I Clinical Trial of XTL-2125
6. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
7. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
8. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
9. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
10. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
11. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon Solution, ... advanced memory and analog IC solutions, today announced that ... July 24, 2014, at 7:00 a.m. Pacific Time (10:00 ... for the fiscal 2014 third quarter ended June 30, ... telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time on ...
(Date:7/10/2014)... JORDAN, Utah , July 10, 2014  BC ... solutions, and MiE America , Inc., a leading ... have entered into a long-term agreement naming BC Technical ... the US. MiE and BC Technical ... strategic agreement to establish BC Technical as the service ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 /PRNewswire/ ... three-quarters of surveyed infectious disease (ID) specialists are ... Medicines Company,s Orbactiv (oritavancin) for use as OPAT, ... to prescribe these agents to their hospital inpatients. ... percent) of OPAT patients are initiated on OPAT ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... ST. LOUIS , Feb. 1 Stereotaxis (Nasdaq: ... featured Dr. Mauricio Arruda , a leading electro-physiologist ... in Cleveland, Ohio , performing a live cardiac ablation ... The patient was a 69 year old woman who suffered ...
... BRISBANE, Calif. , Feb. 1 InterMune, ... Food and Drug Administration,s (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) ... for pirfenidone on March 9, 2010 .  Pirfenidone is ... idiopathic pulmonary fibrosis (IPF).   , "There is an urgent ...
Cached Medicine Technology:Stereotaxis System Procedure Featured on NBC's The TODAY Show 2InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010 2InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010 3InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010 4InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010 5
(Date:7/10/2014)... THURSDAY, July 10, 2014 (HealthDay News) -- Nature, not ... intelligence of individual chimpanzees, a new study finds. ... it comes to cognitive [thinking] abilities in chimpanzees," William ... Atlanta, said in a news release from the journal ... give insight into the evolution of intelligence in humans, ...
(Date:7/10/2014)... THURSDAY, July 10, 2014 (HealthDay News) -- Men who ... aggressive prostate cancer, a new study suggests. But ... several urologists not involved with the study said more ... are truly accurate. For the study, Harvard researchers ... were followed for 24 years, starting in 1986. During ...
(Date:7/10/2014)... More than 200 experts on aggression, who research issues ... attend the 21st World Meeting of the International Society ... Hotel, July 15-19. , Georgia State University is hosting ... year on alternating continents. , "We are excited to ... different countries, which will help produce fresh ideas about ...
(Date:7/10/2014)... of Health and Human Services (HHS) has announced a ... Seidman Cancer Center totaling $4.7 million to support a ... with complex cancer. , Titled "Evidence-Conformant Oncology Care," ... UH to enhance care for adult cancer patients with ... health care utilization. , "We believe that ...
(Date:7/10/2014)... shown that more severe illness and even death are ... infection after developing influenza. Now, however, a team of ... if you reverse the order of infection, the bacteria ... protect against a bad case of the flu. ... which is described as a bacterial virulence factor, might ...
Breaking Medicine News(10 mins):Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2
... ,Hidden Health Tax, is the Undisclosed Premium Surcharge that Pays ... People Join the Ranks of the Uninsured, the ,Hidden Health ... Higher in 2009WASHINGTON, May 28 The so-called ... $1,017 in 2008 according to a report released today by ...
... Elsevier, would like to announce the publication of ... Treatment by Peter Miller, PhD. , The ... the field of addictions treatment is leading to ... based solely on clinical intuition rather than hard ...
... 2009) Kevin Bruhn, PhD, is the winner of the ... at nurturing excellence and providing support for a young scientist ... to LA BioMed in 2005 after receiving his PhD in ... Los Angeles in 2004 and completing a postdoctoral fellowship in ...
... BIRMNGHAM, Ala. An experimental drug derived from cottonseed ... widely considered the most lethal brain cancer, said researchers ... The new results are from a Phase II clinical ... compound in cottonseed that overcomes the abnormal growth patterns ...
... fractional laser was featured today on NBC,s Today ... for scars. During the broadcast, triplets who were severely ... story and discussed recent treatments with the Lumenis UltraPulse ... and DeepFX technologies, the triplets Jordan, Trae and Chandra ...
... Deliciously Cool, Smooth Drink While It,s HotBATTLE CREEK, Mich., May 28 ... season doesn,t feature the bells and whistles of most sought-after new ... to get their hands on it just the same. ... (R) brand is introducing the brand,s first ...
Cached Medicine News:Health News:'Hidden Health Tax' for Family Health Care Coverage Climbed to $1,017 in 2008 2Health News:'Hidden Health Tax' for Family Health Care Coverage Climbed to $1,017 in 2008 3Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 2Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 3Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 4Health News:Special K(R) Brand Shakes Things Up with New Weight-Management Protein Shake 2Health News:Special K(R) Brand Shakes Things Up with New Weight-Management Protein Shake 3Health News:Special K(R) Brand Shakes Things Up with New Weight-Management Protein Shake 4
...
... Miditron Junior II ... urinalysis analyser for standardised ... hardware and software features ... high performance and convenience ...
... The Assistant Free ... retractors utilizing Velcro® straps. ... of the surgeon's operative ... personnel. Three retractor styles ...
... for four corner fusion of the capitate, ... hand. The plate is intended for use ... of function due to SLAC and SNAC ... rheumatoid arthritis. When combined with the specially ...
Medicine Products: